Skip to content
CheckOrphan
  • Home
  • About Us
  • Log In
  • News
    • All News
    • Finance
    • Treatment
    • People
    • Research
  • Videos
  • Treatments
  • Clinical Trials
  • Access Programs
    • About Access Programs
  • Diseases
  • Events
  • Networks
  • Research
Main Menu

Subscribe for Free Newsletter

Email *

Type *

* Required Field
Email Marketing Services by Benchmark

Generate RSS

  1. Home
  2. /
  3. Clinical Trial
  4. /
  5. Clinical Evaluation of Patients...

Clinical Evaluation of Patients With X-linked Retinoschisis

March 6, 2020checkorphan
Learn more about:
X-linked Juvenile Retinoschisis
Related Clinical Trial
Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS) Clinical Evaluation of Patients With X-linked Retinoschisis

Recruitment Information

Administrative Informations

Related News

  • Atsena Therapeutics Completes Part B Dosing in LIGHTHOUSE Trial of ATS
  • Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Reti
  • Atsena Therapeutics Completes Adult Dosing in Part B of the Phase I/II
  • Atsena Therapeutics Announces Alignment with FDA on Regulatory Pathway
  • Atsena Therapeutics Has Been Granted FDA Regenerative Medicine Advance
More News

Related Clinical Trial

  • Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschis
More Clinical Trial

Related Treatment

  • Adeno-associated virus type 8 delivering a vector genome with human re
  • Recombinant adeno-associated viral vector containing the humanretinosc
  • Adeno-associated viral vector expressing human retinoschisin-1 gene
More Treatment

Related

  • Atsena Therapeutics Completes Part B Dosing in LIGHTHOUSE Trial of ATS
  • Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Reti
  • Atsena Therapeutics Completes Adult Dosing in Part B of the Phase I/II
  • Atsena Therapeutics Announces Alignment with FDA on Regulatory Pathway
  • Atsena Therapeutics Has Been Granted FDA Regenerative Medicine Advance
  • Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschis
  • Adeno-associated virus type 8 delivering a vector genome with human re
  • Recombinant adeno-associated viral vector containing the humanretinosc
  • Adeno-associated viral vector expressing human retinoschisin-1 gene
  • National Organization for Rare Disorders
More
pw

About CheckOrphan

CheckOrphan is a non-profit organization located in Basel, Switzerland and Santa Cruz, California that is dedicated to rare, orphan and neglected diseases. CheckOrphan offers users an interactive and dynamic platform for all these diseases. This strategy allows visitors to be updated daily on all the latest news and interact with people internationally. This is essential, because due to the nature of these diseases, there is not a large concentration of individuals within any given proximity.
Click here to know more About Us

Your email is important to us

Each email is sent to a CheckOrphan staff member and will be answered. We only use a contact form to avoid spam.

    Copyright © 2026 CheckOrphan.
    Developed by: Gonza.io logo Developed by: WebOptimalSolutions Powered by: Cloudscale logo